{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:26:38Z","timestamp":1790321198639,"version":"4.1.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T00:00:00Z","timestamp":1577750400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T00:00:00Z","timestamp":1577750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["1RF1AG051514"],"award-info":[{"award-number":["1RF1AG051514"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["1RF1AG057247"],"award-info":[{"award-number":["1RF1AG057247"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["UL1TR002378"],"award-info":[{"award-number":["UL1TR002378"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Insulin impairment and inflammation are two features common to type 2 diabetes and Alzheimer\u2019s disease; however, the molecular and signaling interactions underlying this relationship are not well understood. Mounting evidence point to the associations between the disruption of metabolite processing in insulin impairment and neurodegenerative conditions such as Alzheimer\u2019s. Although the brain depends partially on metabolites processed in the periphery, to date, little is known about how soluble tumor necrosis factor signaling (solTNF) impacts integrated peripheral immune and metabolic feedback signals in states of energy overload and insulin insensitivity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>C57Bl\/6J mice were fed a high-fat high-carbohydrate diet (HFHC) for 14\u2009weeks. The brain-permeant biologic XPro1595\u00ae was used to block solTNF-dependent pathways. Metabolic and immune alterations were evaluated in the gut, liver, and brain. Behavioral tests were performed. Untargeted metabolomics was carried out in the plasma and liver.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>HFHC diet promotes central insulin impairment and dysregulation of immune-modulatory gene expressed in the brain. Alteration of metabolites associated with type 2 diabetes and Alzheimer\u2019s such as butanoate, glutamate, biopterin, branched-chain amino acids, purines, and proteoglycan metabolism was observed in HFHC-fed mice. solTNF inhibition ameliorates hepatic metabolic disturbances and hepatic and intestinal lipocalin-2 levels, and decreases insulin impairment in the brain and behavioral deficits associated with HFHC diet.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our novel findings suggest that HFHC diet impacts central insulin signaling and immune-metabolic interactions in a solTNF-dependent manner to increase the risk for neurodegenerative conditions. Our novel findings indicate that selective solTNF neutralization can ameliorate peripheral and central diet-induced insulin impairment and identify lipocalin-2 as a potential target for therapeutic intervention to target inflammation and insulin disturbances in obesogenic environments. Collectively, our findings identify solTNF as a potential target for therapeutic intervention in inflammatory states and insulin disturbances in obesogenic environments to lower risk for AD.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13195-019-0546-4","type":"journal-article","created":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T09:02:24Z","timestamp":1577782944000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["Targeting soluble tumor necrosis factor as a potential intervention to lower risk for late-onset Alzheimer\u2019s disease associated with obesity, metabolic syndrome, and type 2 diabetes"],"prefix":"10.1186","volume":"12","author":[{"given":"Maria Elizabeth","family":"De Sousa Rodrigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelyn C.","family":"Houser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas I.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean P.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Barnum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mal\u00fa G.","family":"Tansey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,31]]},"reference":[{"issue":"2","key":"546_CR1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrendo.2017.151","volume":"14","author":"Y Zheng","year":"2018","unstructured":"Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88\u201398.","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"546_CR2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrneurol.2017.185","volume":"14","author":"SE Arnold","year":"2018","unstructured":"Arnold SE, et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol. 2018;14(3):168\u201381.","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"546_CR3","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2337\/db11-0390","volume":"61","author":"M Milanski","year":"2012","unstructured":"Milanski M, et al. Inhibition of hypothalamic inflammation reverses diet-induced insulin resistance in the liver. Diabetes. 2012;61(6):1455\u201362.","journal-title":"Diabetes"},{"issue":"2","key":"546_CR4","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s12035-016-9702-z","volume":"54","author":"ZP Mu","year":"2017","unstructured":"Mu ZP, et al. Association between tumor necrosis factor-alpha and diabetic peripheral neuropathy in patients with type 2 diabetes: a meta-analysis. Mol Neurobiol. 2017;54(2):983\u201396.","journal-title":"Mol Neurobiol"},{"issue":"1","key":"546_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/JCI92035","volume":"127","author":"AR Saltiel","year":"2017","unstructured":"Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest. 2017;127(1):1\u20134.","journal-title":"J Clin Invest"},{"issue":"4","key":"546_CR6","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2174\/1567205013666160930110551","volume":"14","author":"B Decourt","year":"2017","unstructured":"Decourt B, Lahiri DK, Sabbagh MN. Targeting tumor necrosis factor alpha for Alzheimer\u2019s disease. Curr Alzheimer Res. 2017;14(4):412\u201325.","journal-title":"Curr Alzheimer Res"},{"key":"546_CR7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fnins.2019.00049","volume":"13","author":"N Orti-Casan","year":"2019","unstructured":"Orti-Casan N, et al. Targeting TNFR2 as a novel therapeutic strategy for Alzheimer\u2019s disease. Front Neurosci. 2019;13:49.","journal-title":"Front Neurosci"},{"issue":"2","key":"546_CR8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/glia.21254","volume":"60","author":"AS Harms","year":"2012","unstructured":"Harms AS, et al. Regulation of microglia effector functions by tumor necrosis factor signaling. Glia. 2012;60(2):189\u2013202.","journal-title":"Glia"},{"issue":"3","key":"546_CR9","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.4049\/jimmunol.179.3.1872","volume":"179","author":"J Zalevsky","year":"2007","unstructured":"Zalevsky J, et al. Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol. 2007;179(3):1872\u201383.","journal-title":"J Immunol"},{"key":"546_CR10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1742-2094-5-45","volume":"5","author":"MK McCoy","year":"2008","unstructured":"McCoy MK, Tansey MG. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation. 2008;5:45.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"546_CR11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.humimm.2015.10.008","volume":"77","author":"I Peluso","year":"2016","unstructured":"Peluso I, Palmery M. The relationship between body weight and inflammation: lesson from anti-TNF-alpha antibody therapy. Hum Immunol. 2016;77(1):47\u201353.","journal-title":"Hum Immunol"},{"issue":"6","key":"546_CR12","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.2337\/db12-0330","volume":"61","author":"PI Mighiu","year":"2012","unstructured":"Mighiu PI, Filippi BM, Lam TK. Linking inflammation to the brain-liver axis. Diabetes. 2012;61(6):1350\u20132.","journal-title":"Diabetes"},{"issue":"4","key":"546_CR13","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1172\/JCI117495","volume":"94","author":"GS Hotamisligil","year":"1994","unstructured":"Hotamisligil GS, et al. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest. 1994;94(4):1543\u20139.","journal-title":"J Clin Invest"},{"issue":"4","key":"546_CR14","doi-asserted-by":"crossref","first-page":"872","DOI":"10.2337\/db09-1541","volume":"59","author":"IK Law","year":"2010","unstructured":"Law IK, et al. Lipocalin-2 deficiency attenuates insulin resistance associated with aging and obesity. Diabetes. 2010;59(4):872\u201382.","journal-title":"Diabetes"},{"issue":"1","key":"546_CR15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1373\/clinchem.2006.075614","volume":"53","author":"Y Wang","year":"2007","unstructured":"Wang Y, et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem. 2007;53(1):34\u201341.","journal-title":"Clin Chem"},{"key":"546_CR16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.neubiorev.2014.12.006","volume":"49","author":"MK Jha","year":"2015","unstructured":"Jha MK, et al. Diverse functional roles of lipocalin-2 in the central nervous system. Neurosci Biobehav Rev. 2015;49:135\u201356.","journal-title":"Neurosci Biobehav Rev"},{"issue":"4","key":"546_CR17","doi-asserted-by":"crossref","first-page":"R160","DOI":"10.1186\/ar3900","volume":"14","author":"A Stavropoulos-Kalinoglou","year":"2012","unstructured":"Stavropoulos-Kalinoglou A, et al. Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis. Arthritis Res Ther. 2012;14(4):R160.","journal-title":"Arthritis Res Ther"},{"key":"546_CR18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1749-6632.2009.05287.x","volume":"1193","author":"MA Gonzalez-Gay","year":"2010","unstructured":"Gonzalez-Gay MA, et al. Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy. Ann N Y Acad Sci. 2010;1193:153\u20139.","journal-title":"Ann N Y Acad Sci"},{"key":"546_CR19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.nbd.2017.02.010","volume":"102","author":"KP MacPherson","year":"2017","unstructured":"MacPherson KP, et al. Peripheral administration of the soluble TNF inhibitor XPro1595 modifies brain immune cell profiles, decreases beta-amyloid plaque load, and rescues impaired long-term potentiation in 5xFAD mice. Neurobiol Dis. 2017;102:81\u201395.","journal-title":"Neurobiol Dis"},{"issue":"5641","key":"546_CR20","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1126\/science.1081297","volume":"301","author":"PM Steed","year":"2003","unstructured":"Steed PM, et al. Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science. 2003;301(5641):1895\u20138.","journal-title":"Science"},{"issue":"43","key":"546_CR21","doi-asserted-by":"crossref","first-page":"12304","DOI":"10.1073\/pnas.1605195113","volume":"113","author":"Y Dong","year":"2016","unstructured":"Dong Y, et al. Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration. Proc Natl Acad Sci U S A. 2016;113(43):12304\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"546_CR22","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.3233\/JAD-170923","volume":"61","author":"B Ahlemeyer","year":"2018","unstructured":"Ahlemeyer B, et al. Endogenous murine amyloid-beta peptide assembles into aggregates in the aged C57BL\/6J mouse suggesting these animals as a model to study pathogenesis of amyloid-beta plaque formation. J Alzheimers Dis. 2018;61(4):1425\u201350.","journal-title":"J Alzheimers Dis"},{"key":"546_CR23","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.3389\/fimmu.2017.01331","volume":"8","author":"F Ungaro","year":"2017","unstructured":"Ungaro F, et al. Actors and factors in the resolution of intestinal inflammation: lipid mediators as a new approach to therapy in inflammatory bowel diseases. Front Immunol. 2017;8:1331.","journal-title":"Front Immunol"},{"issue":"1","key":"546_CR24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nprot.2012.135","volume":"8","author":"EJ Want","year":"2013","unstructured":"Want EJ, et al. Global metabolic profiling of animal and human tissues via UPLC-MS. Nat Protoc. 2013;8(1):17\u201332.","journal-title":"Nat Protoc"},{"key":"546_CR25","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.bbi.2016.08.021","volume":"59","author":"ME de Sousa Rodrigues","year":"2017","unstructured":"de Sousa Rodrigues ME, et al. Chronic psychological stress and high-fat high-fructose diet disrupt metabolic and inflammatory gene networks in the brain, liver, and gut and promote behavioral deficits in mice. Brain Behav Immun. 2017;59:158\u201372.","journal-title":"Brain Behav Immun"},{"issue":"2","key":"546_CR26","doi-asserted-by":"crossref","first-page":"E89","DOI":"10.1152\/ajpendo.00297.2016","volume":"312","author":"Z Fu","year":"2017","unstructured":"Fu Z, et al. Long-term high-fat diet induces hippocampal microvascular insulin resistance and cognitive dysfunction. Am J Physiol Endocrinol Metab. 2017;312(2):E89\u2013e97.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"546_CR27","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/0091-3057(81)90212-4","volume":"15","author":"DR Britton","year":"1981","unstructured":"Britton DR, Britton KT. A sensitive open field measure of anxiolytic drug activity. Pharmacol Biochem Behav. 1981;15(4):577\u201382.","journal-title":"Pharmacol Biochem Behav"},{"issue":"5","key":"546_CR28","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.cell.2012.02.017","volume":"148","author":"VT Samuel","year":"2012","unstructured":"Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012;148(5):852\u201371.","journal-title":"Cell"},{"key":"546_CR29","unstructured":"R Core Team (2018). R: a language and environment for statistical computing. R Foundation for statistical computing, Vienna, Austria. Available online at https:\/\/www.R-project.org\/. Accessed 5 Apr 2018."},{"key":"546_CR30","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/0-387-29362-0_23","volume-title":"Bioinformatics and computational biology solutions using R and Bioconductor","author":"GK Smyth","year":"2005","unstructured":"Smyth GK. Limma: linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W, editors. Bioinformatics and computational biology solutions using R and Bioconductor. New York: Springer; 2005. p. 397\u2013420."},{"key":"546_CR31","unstructured":"Uppal, K. xMSPANDA. (2019). GitHub Repository, https:\/\/github.com\/kuppal2\/xmsPANDA. Accessed 5 Apr 2018."},{"issue":"6","key":"546_CR32","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3390\/jcm8060805","volume":"8","author":"Katarzyna Komosinska-Vassev","year":"2019","unstructured":"Komosinska-Vassev K, Olczyk P, Ku\u017anik-Trocha K, Jura-P\u00f3\u0142torak A, Derkacz A, Purcha\u0142ka M, Telega A, Olczyk K. Circulating C1q\/TNF-Related Protein 3, Omentin-1 and NGAL in Obese Patients with Type 2 Diabetes During Insulin Therapy. J Clin Med. 2019;8(6):805.","journal-title":"Journal of Clinical Medicine"},{"issue":"10","key":"546_CR33","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1172\/JCI90609","volume":"127","author":"T Chitnis","year":"2017","unstructured":"Chitnis T, Weiner HL. CNS inflammation and neurodegeneration. J Clin Invest. 2017;127(10):3577\u201387.","journal-title":"J Clin Invest"},{"issue":"6","key":"546_CR34","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.molmet.2014.06.001","volume":"3","author":"JA Pedroso","year":"2014","unstructured":"Pedroso JA, et al. Inactivation of SOCS3 in leptin receptor-expressing cells protects mice from diet-induced insulin resistance but does not prevent obesity. Mol Metab. 2014;3(6):608\u201318.","journal-title":"Mol Metab"},{"key":"546_CR35","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fnins.2018.00417","volume":"12","author":"L Cao","year":"2018","unstructured":"Cao L, Wang Z, Wan W. Suppressor of cytokine signaling 3: emerging role linking central insulin resistance and Alzheimer\u2019s disease. Front Neurosci. 2018;12:417.","journal-title":"Front Neurosci"},{"issue":"4","key":"546_CR36","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1172\/JCI59903","volume":"122","author":"K Talbot","year":"2012","unstructured":"Talbot K, et al. Demonstrated brain insulin resistance in Alzheimer\u2019s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 2012;122(4):1316\u201338.","journal-title":"J Clin Invest"},{"issue":"2","key":"546_CR37","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.neurobiolaging.2008.04.002","volume":"31","author":"AM Moloney","year":"2010","unstructured":"Moloney AM, et al. Defects in IGF-1 receptor, insulin receptor and IRS-1\/2 in Alzheimer\u2019s disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging. 2010;31(2):224\u201343.","journal-title":"Neurobiol Aging"},{"key":"546_CR38","doi-asserted-by":"publisher","unstructured":"Kaidanovich-Beilin O, Lipina T, Vukobradovic I, Roder J, Woodgett JR. Assessment of social interaction behaviors. J Vis Exp. 2011;(48):2473. https:\/\/doi.org\/10.3791\/2473.","DOI":"10.3791\/2473"},{"issue":"35","key":"546_CR39","doi-asserted-by":"crossref","first-page":"26055","DOI":"10.1016\/S0021-9258(19)74276-8","volume":"268","author":"R Feinstein","year":"1993","unstructured":"Feinstein R, et al. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem. 1993;268(35):26055\u20138.","journal-title":"J Biol Chem"},{"issue":"6","key":"546_CR40","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s10067-013-2369-1","volume":"33","author":"L Costa","year":"2014","unstructured":"Costa L, et al. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol. 2014;33(6):833\u20139.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"546_CR41","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1159\/000088261","volume":"42","author":"H Dominguez","year":"2005","unstructured":"Dominguez H, et al. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res. 2005;42(6):517\u201325.","journal-title":"J Vasc Res"},{"issue":"1","key":"546_CR42","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12933-017-0579-6","volume":"16","author":"W Eilenberg","year":"2017","unstructured":"Eilenberg W, et al. Neutrophil gelatinase associated lipocalin (NGAL) is elevated in type 2 diabetics with carotid artery stenosis and reduced under metformin treatment. Cardiovasc Diabetol. 2017;16(1):98.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"546_CR43","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1055\/s-0032-1331696","volume":"121","author":"T Auguet","year":"2013","unstructured":"Auguet T, et al. Liver lipocalin 2 expression in severely obese women with non alcoholic fatty liver disease. Exp Clin Endocrinol Diabetes. 2013;121(2):119\u201324.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"5","key":"546_CR44","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.tem.2017.01.003","volume":"28","author":"AR Moschen","year":"2017","unstructured":"Moschen AR, et al. Lipocalin-2: a master mediator of intestinal and metabolic inflammation. Trends Endocrinol Metab. 2017;28(5):388\u201397.","journal-title":"Trends Endocrinol Metab"},{"issue":"10","key":"546_CR45","first-page":"2327","volume":"21","author":"J Stallhofer","year":"2015","unstructured":"Stallhofer J, et al. Lipocalin-2 is a disease activity marker in inflammatory bowel disease regulated by IL-17A, IL-22, and TNF-alpha and modulated by IL23R genotype status. Inflamm Bowel Dis. 2015;21(10):2327\u201340.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"546_CR46","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2310\/JIM.0b013e3181ccc20c","volume":"58","author":"D Bolignano","year":"2010","unstructured":"Bolignano D, et al. Neutrophil gelatinase-associated lipocalin levels in patients with crohn disease undergoing treatment with infliximab. J Investig Med. 2010;58(3):569\u201371.","journal-title":"J Investig Med"},{"issue":"19","key":"546_CR47","doi-asserted-by":"crossref","first-page":"14088","DOI":"10.1074\/jbc.M109.017129","volume":"285","author":"JR Karlsen","year":"2010","unstructured":"Karlsen JR, Borregaard N, Cowland JB. Induction of neutrophil gelatinase-associated lipocalin expression by co-stimulation with interleukin-17 and tumor necrosis factor-alpha is controlled by IkappaB-zeta but neither by C\/EBP-beta nor C\/EBP-delta. J Biol Chem. 2010;285(19):14088\u2013100.","journal-title":"J Biol Chem"},{"issue":"9","key":"546_CR48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107265","volume":"9","author":"KA Negrin","year":"2014","unstructured":"Negrin KA, et al. IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis. PLoS One. 2014;9(9):e107265.","journal-title":"PLoS One"},{"key":"546_CR49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41531-016-0002-0","volume":"3","author":"MC Houser","year":"2017","unstructured":"Houser MC, Tansey MG. The gut-brain axis: is intestinal inflammation a silent driver of Parkinson\u2019s disease pathogenesis? NPJ Parkinsons Dis. 2017;3:3.","journal-title":"NPJ Parkinsons Dis"},{"issue":"4","key":"546_CR50","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.cmet.2015.03.001","volume":"21","author":"H Luck","year":"2015","unstructured":"Luck H, et al. Regulation of obesity-related insulin resistance with gut anti-inflammatory agents. Cell Metab. 2015;21(4):527\u201342.","journal-title":"Cell Metab"},{"issue":"1\u20132","key":"546_CR51","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jns.2011.03.023","volume":"305","author":"J Choi","year":"2011","unstructured":"Choi J, Lee HW, Suk K. Increased plasma levels of lipocalin 2 in mild cognitive impairment. J Neurol Sci. 2011;305(1\u20132):28\u201333.","journal-title":"J Neurol Sci"},{"issue":"10","key":"546_CR52","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1038\/cdd.2014.68","volume":"21","author":"SD Mesquita","year":"2014","unstructured":"Mesquita SD, et al. Lipocalin 2 modulates the cellular response to amyloid beta. Cell Death Differ. 2014;21(10):1588\u201399.","journal-title":"Cell Death Differ"},{"issue":"7","key":"546_CR53","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1096\/fj.11-202457","volume":"26","author":"PJ Naude","year":"2012","unstructured":"Naude PJ, et al. Lipocalin 2: novel component of proinflammatory signaling in Alzheimer\u2019s disease. FASEB J. 2012;26(7):2811\u201323.","journal-title":"FASEB J"},{"key":"546_CR54","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3389\/fncel.2013.00122","volume":"7","author":"AC Ferreira","year":"2013","unstructured":"Ferreira AC, et al. Lipocalin-2 is involved in emotional behaviors and cognitive function. Front Cell Neurosci. 2013;7:122.","journal-title":"Front Cell Neurosci"},{"issue":"3","key":"546_CR55","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.molmed.2013.01.002","volume":"19","author":"JA Santiago","year":"2013","unstructured":"Santiago JA, Potashkin JA. Shared dysregulated pathways lead to Parkinson\u2019s disease and diabetes. Trends Mol Med. 2013;19(3):176\u201386.","journal-title":"Trends Mol Med"},{"issue":"10","key":"546_CR56","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41574-018-0048-7","volume":"14","author":"GJ Biessels","year":"2018","unstructured":"Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol. 2018;14(10):591\u2013604.","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"546_CR57","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jalz.2010.06.001","volume":"7","author":"R Kaddurah-Daouk","year":"2011","unstructured":"Kaddurah-Daouk R, et al. Metabolomic changes in autopsy-confirmed Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):309\u201317.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"546_CR58","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2013.18","volume":"3","author":"R Kaddurah-Daouk","year":"2013","unstructured":"Kaddurah-Daouk R, et al. Alterations in metabolic pathways and networks in Alzheimer\u2019s disease. Transl Psychiatry. 2013;3(4):e244.","journal-title":"Transl Psychiatry"},{"issue":"1","key":"546_CR59","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/MCO.0000000000000235","volume":"19","author":"P Giesbertz","year":"2016","unstructured":"Giesbertz P, Daniel H. Branched-chain amino acids as biomarkers in diabetes. Curr Opin Clin Nutr Metab Care. 2016;19(1):48\u201354.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"10","key":"546_CR60","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.2174\/1381612823666170125154915","volume":"23","author":"LM Hiebert","year":"2017","unstructured":"Hiebert LM. Proteoglycans and diabetes. Curr Pharm Des. 2017;23(10):1500\u20139.","journal-title":"Curr Pharm Des"},{"key":"546_CR61","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bbi.2017.01.016","volume":"66","author":"Ryan Rieder","year":"2017","unstructured":"Rieder R, Wisniewsk PJ, Alderman BL, Campbel SC. Microbes and mental health: A review. Brain Behav Immun. 2017;66:9-17.","journal-title":"Brain, Behavior, and Immunity"},{"key":"546_CR62","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fnbeh.2017.00009","volume":"11","author":"EE Noble","year":"2017","unstructured":"Noble EE, Hsu TM, Kanoski SE. Gut to brain dysbiosis: mechanisms linking Western diet consumption, the microbiome, and cognitive impairment. Front Behav Neurosci. 2017;11:9.","journal-title":"Front Behav Neurosci"},{"key":"546_CR63","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3389\/fnins.2015.00173","volume":"9","author":"G van Dijk","year":"2015","unstructured":"van Dijk G, et al. Integrative neurobiology of metabolic diseases, neuroinflammation, and neurodegeneration. Front Neurosci. 2015;9:173.","journal-title":"Front Neurosci"},{"key":"546_CR64","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.neuropharm.2015.10.031","volume":"104","author":"LT Woods","year":"2016","unstructured":"Woods LT, et al. Purinergic receptors as potential therapeutic targets in Alzheimer\u2019s disease. Neuropharmacology. 2016;104:169\u201379.","journal-title":"Neuropharmacology"},{"issue":"8","key":"546_CR65","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2174\/156802611795347555","volume":"11","author":"PL Ipata","year":"2011","unstructured":"Ipata PL, et al. Metabolic network of nucleosides in the brain. Curr Top Med Chem. 2011;11(8):909\u201322.","journal-title":"Curr Top Med Chem"},{"issue":"32","key":"546_CR66","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.2174\/0929867324666170216113756","volume":"25","author":"R Russo","year":"2018","unstructured":"Russo R, et al. Gut-brain axis: role of lipids in the regulation of inflammation, pain and CNS diseases. Curr Med Chem. 2018;25(32):3930\u201352.","journal-title":"Curr Med Chem"},{"issue":"2","key":"546_CR67","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/gutjnl-2018-316155","volume":"68","author":"Y Heianza","year":"2019","unstructured":"Heianza Y, et al. Gut microbiota metabolites, amino acid metabolites and improvements in insulin sensitivity and glucose metabolism: the POUNDS Lost trial. Gut. 2019;68(2):263\u201370.","journal-title":"Gut"},{"issue":"4","key":"546_CR68","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1042\/BCJ20170814","volume":"475","author":"C Morland","year":"2018","unstructured":"Morland C, et al. Propionate enters GABAergic neurons, inhibits GABA transaminase, causes GABA accumulation and lethargy in a model of propionic acidemia. Biochem J. 2018;475(4):749\u201358.","journal-title":"Biochem J"},{"key":"546_CR69","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.matbio.2013.12.009","volume":"35","author":"X Zhang","year":"2014","unstructured":"Zhang X, Wang B, Li JP. Implications of heparan sulfate and heparanase in neuroinflammation. Matrix Biol. 2014;35:174\u201381.","journal-title":"Matrix Biol"},{"issue":"8","key":"546_CR70","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.1074\/jbc.M114.600569","volume":"290","author":"CB Jendresen","year":"2015","unstructured":"Jendresen CB, et al. Overexpression of heparanase lowers the amyloid burden in amyloid-beta precursor protein transgenic mice. J Biol Chem. 2015;290(8):5053\u201364.","journal-title":"J Biol Chem"},{"key":"546_CR71","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.neuroscience.2015.08.002","volume":"305","author":"Q Zhang","year":"2015","unstructured":"Zhang Q, et al. Protective effects of low molecular weight chondroitin sulfate on amyloid beta (Abeta)-induced damage in vitro and in vivo. Neuroscience. 2015;305:169\u201382.","journal-title":"Neuroscience"},{"issue":"4","key":"546_CR72","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1002\/jcp.27153","volume":"234","author":"Clara Iannuzzi","year":"2018","unstructured":"Iannuzzi C, Borriello M, D'Agostino A, Cimini D, Schiraldi C, Sirangelo I. Protective effect of extractive and biotechnological chondroitin in insulin amyloid and advanced glycation end product- induced toxicity. J Cell Physiol. 2019;234(4):3814-3828.","journal-title":"Journal of Cellular Physiology"},{"issue":"9","key":"546_CR73","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.2337\/db12-1242","volume":"62","author":"A Abudukadier","year":"2013","unstructured":"Abudukadier A, et al. Tetrahydrobiopterin has a glucose-lowering effect by suppressing hepatic gluconeogenesis in an endothelial nitric oxide synthase-dependent manner in diabetic mice. Diabetes. 2013;62(9):3033\u201343.","journal-title":"Diabetes"},{"key":"546_CR74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-015-0467-5","volume":"13","author":"DG Kim","year":"2016","unstructured":"Kim DG, et al. Non-alcoholic fatty liver disease induces signs of Alzheimer\u2019s disease (AD) in wild-type mice and accelerates pathological signs of AD in an AD model. J Neuroinflammation. 2016;13:1.","journal-title":"J Neuroinflammation"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-019-0546-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-019-0546-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-019-0546-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T14:07:26Z","timestamp":1695564446000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-019-0546-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,31]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["546"],"URL":"https:\/\/doi.org\/10.1186\/s13195-019-0546-4","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,31]]},"assertion":[{"value":"14 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experiments were approved by the Institutional Animal Care and Use Committee of Emory University and followed the guidelines established by the National Institutes of Health Guide for the Care and Use of Laboratory Animals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have consented to publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MG Tansey is an ex-employee of Xencor, Inc. and is a co-inventor on the dominant-negative TNF patent but does not hold a significant financial stake in Xencor, Inc. or INmune Bio, Inc. CJ Barnum is an employee of INmune Bio. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}